Sodium in PDB 9vm1: Mvm NS2 Mutant NM42 in Complex with CRM1-Ran-RANBP1

The structure of Mvm NS2 Mutant NM42 in Complex with CRM1-Ran-RANBP1, PDB code: 9vm1 was solved by Q.Sun, Y.Li, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å)	86.85 / 2.45
Space group	P 43 21 2
Cell size a, b, c (Å), α, β, γ (°)	105.92, 105.92, 303.45, 90, 90, 90
R / Rfree (%)	19.8 / 23.5

The structure of Mvm NS2 Mutant NM42 in Complex with CRM1-Ran-RANBP1 also contains other interesting chemical elements:

Magnesium

(Mg)

1 atom

The binding sites of Sodium atom in the Mvm NS2 Mutant NM42 in Complex with CRM1-Ran-RANBP1 (pdb code 9vm1). This binding sites where shown within 5.0 Angstroms radius around Sodium atom.
In total only one binding site of Sodium was determined in the Mvm NS2 Mutant NM42 in Complex with CRM1-Ran-RANBP1, PDB code: 9vm1:

Sodium binding site 1 out of 1 in the Mvm NS2 Mutant NM42 in Complex with CRM1-Ran-RANBP1


Mono view


Stereo pair view

A full contact list of Sodium with other atoms in the Na binding site number 1 of Mvm NS2 Mutant NM42 in Complex with CRM1-Ran-RANBP1 within 5.0Å range: probe atom residue distance (Å) B Occ C:Na1102 b:75.0 occ:1.00 OH C:TYR465 2.4 58.6 1.0 OH C:TYR557 2.6 57.8 1.0 O C:TRP510 2.9 59.7 1.0 CZ C:TYR465 3.3 60.3 1.0 C C:GLY513 3.3 59.5 1.0 N C:SER514 3.4 58.1 1.0 CZ C:TYR557 3.5 58.3 1.0 CE1 C:TYR465 3.5 59.0 1.0 CE2 C:TYR557 3.5 58.6 1.0 CA C:SER514 3.7 58.7 1.0 CA C:GLY513 3.7 59.8 1.0 NE2 C:GLN561 3.7 60.5 1.0 O C:GLY513 3.7 60.8 1.0 C C:TRP510 3.9 58.8 1.0 CB C:SER514 4.0 58.5 1.0 CD C:GLN561 4.0 59.3 1.0 CG C:GLN561 4.0 60.8 1.0 CA C:TRP510 4.1 60.2 1.0 CG C:PRO438 4.4 68.4 1.0 N C:GLY513 4.5 59.9 1.0 O C:HOH1358 4.5 73.0 1.0 CE2 C:TYR465 4.6 57.5 1.0 CB C:TRP510 4.7 59.4 1.0 CE1 C:TYR557 4.8 58.1 1.0 OE1 C:GLN561 4.8 61.4 1.0 CD1 C:TYR465 4.8 58.1 1.0 CD2 C:TYR557 4.8 58.0 1.0

M.Sui, M.Xiong, Y.Li, Q.Zhou, X.Shen, D.Jia, M.Gou, Q.Sun. Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor. Int J Nanomedicine V. 16 2833 2021.
ISSN: ISSN 1178-2013
PubMed: 33883894
DOI: 10.2147/IJN.S266398